🇺🇸 FDA
Pipeline program

APG777

APG777-202

Phase 2 small_molecule active

Quick answer

APG777 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Apogee Therapeutics with 3 ClinicalTrials.gov record(s).

Program details

Company
Apogee Therapeutics
Indication
Atopic Dermatitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials